Qilu Pharmaceutical

Large vertically-integrated Chinese pharma (FDF + API manufacturer)

Privately held: no public share price · China

Assets

(22 total)
22Total Assets
0Approved
14Phase 3 / Filed
8Phase 1–2 / Early
13Diseases
Quick filter:
Showing 22 of 22 assets
Target & Modality
Phase 3
AKT (inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D3/D2 receptor (partial agonist)Small molecule
Schizophrenia
Phase 3
PD-1Monoclonal antibody
Indication not yet linked
Phase 3
PD-1 x CTLA-4Multispecific antibody
Non-Small Cell Lung CancerColorectal Cancer
Metastatic Colorectal Cancer
Phase 3
ALK;ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 3
Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist) · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Phase 3
IL-23 p19Monoclonal antibody
Psoriasis
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 3
JAKSmall molecule
Atopic Dermatitis
Phase 3
GPRC5D x CD3Multispecific antibody
Multiple Myeloma
Phase 3
GPRC5D x BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
Phase 2
IRAK4Small molecule
Atopic Dermatitis

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
QLS1410Phase 2Hypertension (HTN)
Est. primary completion 2026-12 · NCT07489612 · CT.gov ↗
What to watch
RAY1225Phase 3T2DM
Est. primary completion 2026-12-01 · NCT07139535 · CT.gov ↗
What to watch
RAY1225Phase 3T2DM
Est. primary completion 2026-12-01 · NCT07139548 · CT.gov ↗
What to watch
2027 (18)
February 2027 (1)
Iparomlimab and tuvonralimabPhase 2Recurrent Cervical Cancer
Est. primary completion 2027-02-28 · NCT07172217 · CT.gov ↗
What to watch
March 2027 (1)
QLM3003Phase 3Atopic Dermatitis
Est. primary completion 2027-03 · NCT06880276 · CT.gov ↗
What to watch
April 2027 (2)
Iparomlimab and tuvonralimab + QLS5132Phase 1/2Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
QLS1410Phase 2Primary Aldosteronism
Est. primary completion 2027-04 · NCT07550465 · CT.gov ↗
What to watch
May 2027 (1)
QL2108Phase 3Atopic Dermatitis
Est. primary completion 2027-05 · NCT06884891 · CT.gov ↗
What to watch
June 2027 (3)
Iparomlimab and tuvonralimabPhase 1/2Metastatic Solid Tumors
Est. primary completion 2027-06 · NCT07272590 · CT.gov ↗
What to watch
QLS12010Phase 2Adults With Moderate-to-severe Hidradenitis Suppurativa
Est. primary completion 2027-06-01 · NCT07417917 · CT.gov ↗
What to watch
Iparomlimab and tuvonralimabPhase 2Colon Cancer, MSS/pMMR, QL1706
Est. primary completion 2027-06-30 · NCT07156682 · CT.gov ↗
What to watch
August 2027 (1)
Iparomlimab and tuvonralimabPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-08-31 · NCT05487391 · CT.gov ↗
What to watch
September 2027 (2)
QLS12010Phase 2Moderate-to-severe Atopic Dermatitis
Est. primary completion 2027-09 · NCT07344051 · CT.gov ↗
What to watch
Iparomlimab and tuvonralimabPhase 2/3Hepatocellular Carcinoma
Est. primary completion 2027-09-01 · NCT05976568 · CT.gov ↗
What to watch
October 2027 (1)
QLC7401Phase 3Primary Hypercholesterolemia or Mixed Hyperlipidemia
Est. primary completion 2027-10-07 · NCT07444086 · CT.gov ↗
What to watch
November 2027 (1)
QLS32015 + QL2109Phase 2Relapsed or Refractory Multiple Myeloma
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
December 2027 (5)
QLS1410Phase 2Uncontrolled Hypertension
Est. primary completion 2027-12 · NCT07927556 · CT.gov ↗
What to watch
QLC7401Phase 3Primary Hypercholesterolemia or Mixed Hyperlipidemia
Est. primary completion 2027-12 · NCT07441317 · CT.gov ↗
What to watch
QL2109Phase 3Multiple Myeloma
Est. primary completion 2027-12 · NCT06742138 · CT.gov ↗
What to watch
QLS32015Phase 3Relapsed or Refractory Multiple Myeloma
Est. primary completion 2027-12 · NCT07138209 · CT.gov ↗
What to watch
QL2106Phase 3Plaque Psoriasis
Est. primary completion 2027-12-30 · NCT07511647 · CT.gov ↗
What to watch
2028 (6)
March 2028 (2)
Iparomlimab and tuvonralimabPhase 3Small-cell Lung Cancer
Est. primary completion 2028-03 · NCT06789796 · CT.gov ↗
What to watch
QLS12010Phase 2Rheumatoid Arthritis (RA)
Est. primary completion 2028-03-05 · NCT07377773 · CT.gov ↗
What to watch
April 2028 (1)
QLC7401Phase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2028-04 · NCT07450378 · CT.gov ↗
What to watch
June 2028 (1)
QLS4131 + QL2109Phase 2Malignant Plasma Cell Neoplasms
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
July 2028 (1)
Iparomlimab and tuvonralimabPhase 3Metastatic Colorectal Cancer
Est. primary completion 2028-07 · NCT07025239 · CT.gov ↗
What to watch
November 2028 (1)
QLS1304Phase 1/2Advanced ER+/HER2- Breast Cancer
Est. primary completion 2028-11-02 · NCT07235176 · CT.gov ↗
What to watch
2029 (3)
June 2029 (1)
Est. primary completion 2029-06 · NCT05690945 · CT.gov ↗
What to watch
December 2029 (2)
QLS5132Phase 3Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2029-12 · NCT07926048 · CT.gov ↗
What to watch
QLS4131Phase 3Relapsed or Refractory Multiple Myeloma
Est. primary completion 2029-12-14 · NCT07933432 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Iparomlimab and tuvonralimabPhase 2Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2030-12 · NCT06852456 · CT.gov ↗
What to watch
Iparomlimab and tuvonralimabPhase 3Colon Cancer
Est. primary completion 2030-12 · NCT06686576 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 October 2026Topline resultRAY1225Phase 3 REBUILDING-2 obesity trial met its primary endpoint
CN · Guangdong Zhongsheng Pharmaceutical (SZSE 002317), parent of Guangdong Raynovent Biotech · Source ↗
11 August 2026Filing acceptedAfuresertib (GSK2110183)China NMPA accepts afuresertib NDA
CN, NMPA · Laekna · Source ↗
15 April 2026Topline resultAfuresertibAFFIRM-205 Phase 3 (NCT04851613) met its primary endpoint of PFS
Laekna · Source ↗
6 December 2023Topline resultIparomlimab (QL1604)Qilu reports the pivotal Phase 2 result of iparomlimab in dMMR/MSI-H solid tumors (ORR 45.8%)
Qilu Pharmaceutical · Source ↗
September 2023Filing acceptedIparomlimab (QL1604)China's CDE accepts the new drug application for iparomlimab in dMMR/MSI-H solid tumors
CN, NMPA · Qilu Pharmaceutical · Source ↗
17 August 2023Filing acceptedWX-0593China CDE accepts iruplinalkib first-line NDA
CN, NMPA · Qilu Pharmaceutical · Source ↗

Financial reports

No financial reports recorded.